D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 80 Citations 29,646 259 World Ranking 9464 National Ranking 425

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • DNA

Marcel Kool mainly focuses on Medulloblastoma, Bioinformatics, Genetics, Cancer research and Molecular biology. His Medulloblastoma study combines topics from a wide range of disciplines, such as Clinical trial, Gene expression profiling, Transcriptome, Genomics and Human genetics. His Bioinformatics research includes themes of Cancer, Comparative genomic hybridization, Disease and X chromosome.

His study in Cancer research is interdisciplinary in nature, drawing from both Mutation, IDH1, Enhancer, Epigenetics and PTCH1. His Epigenetics research incorporates elements of Epigenomics, Epigenesis, DNA methylation and Exome. His biological study spans a wide range of topics, including Mutant, Gene, Cell culture and Multidrug resistance-associated protein 2.

His most cited work include:

  • Signatures of mutational processes in human cancer (5372 citations)
  • Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma (1542 citations)
  • A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins (1450 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Cancer research, Medulloblastoma, Pathology, DNA methylation and Internal medicine. The concepts of his Cancer research study are interwoven with issues in Mutation, Gene, Carcinogenesis and SMARCB1. Marcel Kool works mostly in the field of Medulloblastoma, limiting it down to topics relating to Bioinformatics and, in certain cases, Genomics.

The DNA methylation study combines topics in areas such as Methylation, Epigenetics and Ependymoma. Epigenetics is a subfield of Genetics that he studies. His study explores the link between Internal medicine and topics such as Oncology that cross with problems in Clinical trial and Disease.

He most often published in these fields:

  • Cancer research (39.45%)
  • Medulloblastoma (35.18%)
  • Pathology (20.68%)

What were the highlights of his more recent work (between 2019-2021)?

  • Cancer research (39.45%)
  • Medulloblastoma (35.18%)
  • DNA methylation (19.19%)

In recent papers he was focusing on the following fields of study:

Marcel Kool mainly investigates Cancer research, Medulloblastoma, DNA methylation, Internal medicine and Oncology. His Cancer research study combines topics from a wide range of disciplines, such as Mutation, Suppressor, Transcriptome, Carcinogenesis and Germline. Within one scientific family, Marcel Kool focuses on topics pertaining to PTCH1 under Medulloblastoma, and may sometimes address concerns connected to Epigenetics.

His work deals with themes such as Germline mutation, Methylation, SMARCB1 and Pathology, which intersect with DNA methylation. In his work, Validation cohort and Chemotherapy is strongly intertwined with Clinical trial, which is a subfield of Oncology. Marcel Kool has included themes like Computational biology and Ependymoma in his Gene study.

Between 2019 and 2021, his most popular works were:

  • Pan-cancer analysis of whole genomes (538 citations)
  • An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. (42 citations)
  • Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. (32 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • DNA

His primary areas of study are Cancer research, Medulloblastoma, Pathology, DNA methylation and Brain tumor. His study in Cancer research is interdisciplinary in nature, drawing from both Carcinogenesis, Gene expression, Chemotherapy and Mutation. His Medulloblastoma research is multidisciplinary, incorporating elements of Oncology, Transcriptome, Sonic hedgehog, PTCH1 and Internal medicine.

His Sonic hedgehog research is included under the broader classification of Genetics. His Pathology study incorporates themes from Genetic heterogeneity and Oligodendroglioma. His DNA methylation research integrates issues from Bone Sarcoma, Papillary tumor and Methylation.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Signatures of mutational processes in human cancer

Ludmil B. Alexandrov;Serena Nik-Zainal;Serena Nik-Zainal;David C. Wedge;Samuel A. J. R. Aparicio.
Nature (2013)

6684 Citations

A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins

Piet Borst;Raymond Evers;Marcel Kool;Jan Wijnholds.
Journal of the National Cancer Institute (2000)

2142 Citations

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

Jeremy Schwartzentruber;Andrey Korshunov;Xiao Yang Liu;David T.W. Jones.
Nature (2012)

1923 Citations

Molecular Subgroups of Medulloblastoma: The Current Consensus

Michael D. Taylor;Paul A. Northcott;Andrey Korshunov;Marc Remke;Marc Remke.
Acta Neuropathologica (2012)

1490 Citations

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Dominik Sturm;Hendrik Witt;Hendrik Witt;Volker Hovestadt;Dong Anh Khuong-Quang.
Cancer Cell (2012)

1438 Citations

Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.

M. Kool;M. De Haas;G. L. Scheffer;R. J. Scheper.
Cancer Research (1997)

1115 Citations

DNA methylation-based classification of central nervous system tumours

David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt.
Nature (2018)

860 Citations

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

Marcel Kool;Andrey Korshunov;Marc Remke;Marc Remke;David T.W. Jones.
Acta Neuropathologica (2012)

845 Citations

The multidrug resistance protein family.

Piet Borst;Raymond Evers;Marcel Kool;Jan Wijnholds.
Biochimica et Biophysica Acta (1999)

839 Citations

Dissecting the genomic complexity underlying medulloblastoma

David T. W. Jones;Natalie Jäger;Marcel Kool;Thomas Zichner.
Nature (2012)

777 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Marcel Kool

Stefan M. Pfister

Stefan M. Pfister

German Cancer Research Center

Publications: 309

Michael D. Taylor

Michael D. Taylor

University of Toronto

Publications: 231

Andreas von Deimling

Andreas von Deimling

Heidelberg University

Publications: 227

Felix Sahm

Felix Sahm

University Hospital Heidelberg

Publications: 158

David T. W. Jones

David T. W. Jones

German Cancer Research Center

Publications: 149

David Capper

David Capper

Humboldt-Universität zu Berlin

Publications: 139

Wolfgang Wick

Wolfgang Wick

German Cancer Research Center

Publications: 133

Peter J. Campbell

Peter J. Campbell

Wellcome Sanger Institute

Publications: 130

Cynthia Hawkins

Cynthia Hawkins

University of Toronto

Publications: 112

Eric Bouffet

Eric Bouffet

University of Toronto

Publications: 103

Ludmil B. Alexandrov

Ludmil B. Alexandrov

University of California, San Diego

Publications: 99

Torsten Pietsch

Torsten Pietsch

University of Bonn

Publications: 94

Gad Getz

Gad Getz

Broad Institute

Publications: 93

Michael Weller

Michael Weller

University of Zurich

Publications: 91

Rameen Beroukhim

Rameen Beroukhim

Harvard University

Publications: 86

Arie Perry

Arie Perry

University of California, San Francisco

Publications: 82

Something went wrong. Please try again later.